[go: up one dir, main page]

MX2009011500A - Anticuerpos anti-mdl-1. - Google Patents

Anticuerpos anti-mdl-1.

Info

Publication number
MX2009011500A
MX2009011500A MX2009011500A MX2009011500A MX2009011500A MX 2009011500 A MX2009011500 A MX 2009011500A MX 2009011500 A MX2009011500 A MX 2009011500A MX 2009011500 A MX2009011500 A MX 2009011500A MX 2009011500 A MX2009011500 A MX 2009011500A
Authority
MX
Mexico
Prior art keywords
antibodies
mdl
sepsis
treatment
well
Prior art date
Application number
MX2009011500A
Other languages
English (en)
Inventor
Leonard G Presta
Joseph H Phillips
Michael E Bigler
Paul Geoffrey Heyworth
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009011500A publication Critical patent/MX2009011500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos para MDL-1 humana, así como usos de la misma, por ejemplo, en el tratamiento de trastornos inmunes, en particular, para enfermedades infecciosas y sepsis.
MX2009011500A 2007-04-23 2008-04-21 Anticuerpos anti-mdl-1. MX2009011500A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91343607P 2007-04-23 2007-04-23
US94471407P 2007-06-18 2007-06-18
PCT/US2008/005128 WO2008133857A1 (en) 2007-04-23 2008-04-21 Anti-mdl-1 antibodies

Publications (1)

Publication Number Publication Date
MX2009011500A true MX2009011500A (es) 2010-01-29

Family

ID=39708758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011500A MX2009011500A (es) 2007-04-23 2008-04-21 Anticuerpos anti-mdl-1.

Country Status (7)

Country Link
US (1) US8153134B2 (es)
EP (1) EP2152750A1 (es)
JP (1) JP2010526066A (es)
CN (1) CN101986783A (es)
CA (1) CA2685015A1 (es)
MX (1) MX2009011500A (es)
WO (1) WO2008133857A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943134B2 (en) * 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CA2691618A1 (en) * 2007-06-29 2009-01-08 Schering Corporation Mdl-1 uses
AU2008326348B2 (en) 2007-11-21 2014-01-30 Oregon Health & Science University Anti-factor XI monoclonal antibodies and methods of use thereof
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
KR102295746B1 (ko) * 2011-10-28 2021-09-01 리제너론 파아마슈티컬스, 인크. 유전자 변형된 주요 조직적합성 복합체 마우스
KR102159109B1 (ko) 2011-11-16 2020-09-23 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
SI2847228T1 (sl) 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
EP2885311B1 (en) 2012-08-18 2020-01-01 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CA2883168A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
KR102298172B1 (ko) 2013-09-06 2021-09-06 아카데미아 시니카 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20240096599A (ko) 2014-05-27 2024-06-26 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
AU2015267052A1 (en) 2014-05-27 2016-12-15 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
CN107001404B (zh) 2014-09-08 2021-06-29 中央研究院 使用醣脂激活人类iNKT细胞
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
TWI717333B (zh) * 2015-01-30 2021-02-01 中央研究院 增進抗體功效之通用糖型組合物及方法
US20180346571A1 (en) * 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
CA3029332A1 (en) * 2016-07-01 2018-01-04 Ludwig Institute For Cancer Research Ltd Methods and compositions for pdgf-cc inhibition
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CA3132917A1 (en) 2019-03-08 2020-09-17 Boehringer Ingelheim International Gmbh Anti-il-36r antibody formulations
WO2021030423A1 (en) * 2019-08-13 2021-02-18 The Feinstein Institutes For Medical Research Tetranectin-targeting monoclonal antibodies to fight against lethal sepsis and other pathologies
EP4090433A4 (en) * 2020-01-16 2024-02-14 Caerus Therapeutics, Inc. HUMANIZED ANTIBODIES SPECIFIC FOR OVARIAN CANCER AND MYELOMA CELLS
KR20230038774A (ko) 2020-07-17 2023-03-21 베링거 인겔하임 인터내셔날 게엠베하 호중성 피부병의 치료를 위한 항-il-36r 항체
WO2022133318A2 (en) * 2020-12-18 2022-06-23 Single Cell Technology, Inc. Anti-sars corona virus-2 nucleocapsid protein antibodies
AU2022241762A1 (en) * 2021-03-24 2023-09-14 Mural Oncology, Inc. Upar antibodies and fusion proteins with the same
CN116621976B (zh) * 2023-07-04 2024-02-09 浙江大学 抗PDCoV核衣壳蛋白的单克隆抗体2H7及其应用方法
CN119306826B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗白介素-6抗体、检测白介素-6的试剂和试剂盒
WO2025011639A1 (zh) * 2023-07-13 2025-01-16 深圳泽安生物医药有限公司 多特异性抗体及其用途
US20250313644A1 (en) * 2024-01-26 2025-10-09 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Antibodies capable of specifically binding tl1a and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1003861E (pt) 1997-08-01 2007-01-31 Schering Corp Proteínas de membrana de células de mamíferos;reagentes relacionados
US6416973B1 (en) * 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
WO2006052975A2 (en) * 2004-11-08 2006-05-18 Schering Corporation Tumor association of mdl-1 and methods

Also Published As

Publication number Publication date
CA2685015A1 (en) 2008-11-06
JP2010526066A (ja) 2010-07-29
CN101986783A (zh) 2011-03-16
WO2008133857A1 (en) 2008-11-06
US20100150945A1 (en) 2010-06-17
EP2152750A1 (en) 2010-02-17
US8153134B2 (en) 2012-04-10

Similar Documents

Publication Publication Date Title
MX2009011500A (es) Anticuerpos anti-mdl-1.
CY1123404T1 (el) Αντι-girt αντισωματα
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
MX2011012060A (es) Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-miloide.
EA201101530A1 (ru) ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
IN2012DN02737A (es)
MY158992A (en) Forms of rifaximin and uses thereof
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX2011011670A (es) Inmunoglobulinas de dominio variable dual y usos de las mismas.
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
TN2011000374A1 (en) Antibody molecules having specificity for human ox40
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MY147217A (en) Antibody molecules having specificity for human il-06
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
IL194353A0 (en) Lysobactin amides
ATE410443T1 (de) Heterocyclyl-substituierte nonadepsipeptide
ATE455789T1 (de) Substituierte nonadepsipeptide
AU2017221784B2 (en) Novel compositions and methods for the treatment of immune related diseases
WO2010019565A3 (en) Anti-ephrin b2 antibodies and their use in treatment of disease
HK1127070A (en) Engineered anti-il-23p19 antibodies